Myelogenous Leukemia, Acute
9
0
1
4
Key Insights
Highlights
Success Rate
67% trial completion
Treatment Research
20 treatments under study, led by Cytarabine
Research Leaders
9 sponsors active, led by Roche
Related Conditions
Often studied with 20 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
22.2%
2 terminated out of 9 trials
66.7%
-19.9% vs benchmark
11%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (9)
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Bisantrene Combination for Resistant AML
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia
A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Research Network
Common Treatments
- Cytarabine4
- Fludarabine2
- Conventional Care1
- 131iapamistamab1
- Cyclophosphamide1
Active Sponsors
- Roche3
- Actinium Pharmaceuticals2
- Merck Sharp & Dohme LLC1
- Brigham and Women's Hospital1
- Mirati Therapeutics Inc.1
Top Investigators
Actinium Pharmaceuticals
Sheba Medical Center
Dana-Farber Cancer Institute
MethylGene Inc.
Related Conditions
- Acute Myelogenous Leukemia2
- Acute Myeloid Leukemia2
- Myelogenous Leukemia1
- Myeloid Leukemia Acute1
- Refractory Aml1